This study was conducted to assess spinal safety of the cyclooxygenase inhibitor ketorolac in dogs and rats. Beagle dogs were prepared with lumbar intrathecal catheters and received continuous spinal infusions of 5 mg/ml ketorolac (N 5 6), 0.5 mg/ml ketorolac (N 5 8), or saline vehicle (N 5 6) at 50 ml/h (1.2 ml/day) for 28 days. No systematic drug or dose-related changes were observed in motor function, heart rate, or blood pressure. Histological examination revealed a mild pericatheter reaction in all groups with no drug or dose related effect upon spinal pathology at the lumbar site of highest drug concentration. Cisternal CSF protein was elevated for all treatment groups at necropsy, and cisternal glucose was within normal range for all treatment groups, though three dogs displayed decreases in cisternal glucose. Significant reductions in hematocrit were noted, and increased incidence of gastric bleeding at necropsy was observed in animals receiving ketorolac. Intrathecal ketorolac kinetics revealed a biphasic clearance: t1/2s 5 10.3 and 53 min, respectively. After initiation of infusion (0.5 mg and 5 mg/ml/ 50 ml/h), lumbar CSF concentrations of ketorolac were 3.8 and 52.7 mg/ml, respectively. Bolus and continuous infusion of intrathecal ketorolac resulted in significant reduction of lumbar CSF PGE2 concentrations. In rats, with intrathecal catheters, four daily bolus deliveries of saline or ketorolac (5 mg/ml/10 ml) had no effect upon spinal histology or upon spinal cord blood flow. These data indicate that intrathecal ketorolac in two species at the dose/concentrations employed does not induce evident spinal pathology but diminishes spinal prostaglandin release.
Following tissue injury and inflammation a behaviorally defined hyperalgesia can be identified in animal models and in humans (Yaksh et al., 1999a) . Current thinking suggests that this behavioral syndrome results from the chronic activation of primary afferent input and/or the presence of circulating cytokines that initiate a spinal cascade that serves to sensitize spinal nociceptive processing. An important component of this cascade appears to be the synthesis and extracellular movement of prostaglandins through an activation of spinal cyclooxygenase Yaksh, 2002, Yaksh et al., 2001) . Thus, previous studies have shown that a variety of COX inhibitors, such as acetylsalicylate, ibuprofen, and ketorolac given intrathecally in rat models will diminish hyperalgesic states at intrathecal doses thatare100to300timessmallerthanthoserequiredaftersystemic delivery and that have no evident effects after systemic delivery (MalmbergandYaksh,1992a,b; Yaksh,1982; Yakshetal.,2001) .
Ketorolac is a water-soluble nonsteroidal anti-inflammatory drug (NSAID) with potent inhibitor effects upon both cyclooxygenase isozymes. Administered systemically in humans, ketorolac has potent antihyperalgesic actions in postoperative pain (Gillies et al., 1987) . Its limiting effects are gastrointestinal ulceration, effects upon renal blood flow, and depressed platelet function. These effects are believed to be common to the blockade of peripheral systemic cyclooxygenase isozyme activity (Eisenberg et al., 1994) . These potent effects of cyclo-oxygenase (COX) inhibitors on hyperalgesic states in humans suggest that, as in preclinical models, the spinal delivery of COX inhibitors may also display significant efficacy with diminished systemic side effects.
To consider the possible reaction of intrathecal ketorolac in humans, it is necessary to establish the pharmacokinetics and the effects upon spinal cord after intrathecal delivery in well-defined preclinical models that are believed to robustly define the safety (or lack thereof) of the test articles in question. These studies should be undertaken at the maximum usable formulation of the GMP (Good Manufacturing Practice) product. The present study was conducted to obtain such data.
The dog and rat are species routinely used to satisfy regulatory requirements for drug safety evaluation and are chosen because there is considerable knowledge of these species' responses to a wide variety of intrathecal drugs (Yaksh and Malkmus, 1999; Yaksh et al., 1999b) .
MATERIALS AND METHODS
All animal work was carried out according to protocols approved by the Institutional Animal Care and Use Committee of the University of California, San Diego and was in compliance with the USDA Animal Welfare Act (USDA Title 9 Code of Federal Regulations Part 3, Federal Register 15 February 1991).
Animals
Dogs. Beagle dogs (Covance, Inc., Princeton, NJ and Marshall Farms, Inc., North Rose, NY), 10 to 24 months in age and weighing 6 to 12 kg, were individually housed in runs with wood shavings and given ad libitum access to food and water with a daily 12-h light/dark cycle. Kennels were maintained within the range of 62-82 F. Animals were adapted for a minimum of 10 days prior to surgery. A nylon vest (Alice King Chatham Medical Arts, Hawthorne, CA) was placed on each dog approximately 48 h prior to intrathecal catheter placement surgery for acclimation.
Rats. Male Sprague-Dawley rats (Harlan-Industries, Indianapolis, IN), 250-370 g, were individually housed and given ad libitum access to food and water in a regulated temperature (66-76 F) and illumination (12 h light/ 12 h dark) environment. Body weight was assessed before implantation of the intrathecal catheter and daily during study drug treatment.
Surgical Preparation
Dog. To permit chronic delivery of drug into the lumbar intrathecal space, a catheter was passed from the cisterna magna to the lumbar intrathecal space. This placement was accomplished approximately 72 h prior to intrathecal dosing. The antibiotic sulfamethoxazole-trimethoprim (240 mg tablet, 15-25 mg/kg, po, twice daily) was given 48 h prior to surgery and for 48 h after surgery. Dogs received atropine (0.04 mg/kg, im) prior to sedation with xylazine (1.5 mg/kg, im). Anesthesia was induced with isoflurane, 1-2% in N 2 O/oxygen (60/40%) with a mask followed by endotracheal intubation and spontaneous ventilation. Animals were continuously monitored for oxygen saturation, inspired and end tidal values of isoflurane, CO 2 , N 2 O and oxygen and heart and respiratory rates.
Surgical areas were shaved and prepared with chlorhexadine scrub and solution. Using sterile technique, the cisterna magna was exposed and a small incision (1-2 mm) was made in the dura. APE-10 l catheter (fabricated with polyethylene tubing and sterilized by electron beam irradiation) was inserted and passed caudally approximately 40 cm to a level corresponding to the L 2-3 segment. Dexamethasone sodium phosphate (0.25 mg/kg, im) was administered just after catheter placement. The external catheter was then tunneled subcutaneously to exit at the left scapular region. Upon closure of the incision, isoflurane was discontinued and butorphanol tartrate (Torbugesic; 0.04 mg/kg, im) was administered to relieve postoperative pain as necessary.
For pharmacokinetic studies, dogs were prepared as described above, but a second catheter (polyethylene, PE50) was also placed in addition to the infusion catheter for purposes of lumbar cerebrospinal fluid (CSF) sampling. The sampling catheter was passed such that the tip was approximately 2 cm cephalad to the infusion site. The catheter was externalized similarly on the contralateral side.
Following recovery, the nylon vest was again placed on the animal (animals having been previously acclimated to the vest prior to surgery), and an infusion pump (PANOMAT C-10; Disetronic Medical Systems, Saint Paul, MN) secured in the vest pocket where it was connected to the externalized end of the PE-10 intrathecal catheter. An infusion of 0.9% (w/v) Sodium Chloride for Injection, USP at 50 ml/h was initiated to ensure catheter patency prior to infusion of Test Article.
Rats. For neurotoxicologic assessment, rats were anesthetized with 2-4% halothane in oxygen/air. Polyethylene catheters were inserted through a small incision in the atlanto-occipital membrane and passed 8 cm caudally to the level of the lumbar enlargement, as previously described (Yaksh and Rudy, 1976) . To confirm correct placement of the catheters, 10 ml of 2% lidocaine was injected, followed by a 10 ml 0.9% saline flush the day after surgery. All animals developing a bilateral motor block of the hind limbs within 30 s were included in the study. After surgery and testing with lidocaine, the animals recovered for at least five days. Animals with any evident neurologic deficit were excluded from the study.
Test Article
Ketorolac (5 mg/ml; Acular PF TM ; Allergan, Irvine, CA) was supplied as a sterile additive-free saline solution. Sterile saline (0.9% (w/v) Sodium Chloride for Injection, USP, Abbott Laboratories, North Chicago, IL; 10 ml/vial) was used as the control solution and as flush for the catheter. From each cartridge change of the test article treatment group, drug samples were randomly collected during the filling of the pump cartridges and analyzed for test article concentration.
Dog Procedures
These studies had three phases: dose ranging, safety, and pharmacokinetics. Table 1 indicates the dog treatment assignments.
Dose-ranging phase. Two dogs were assigned to receive the maximum concentrations (5 mg/ml) at the maximum intrathecal infusion rate routinely employed for spinal delivery in this model (100 ml/h). In the event of deleterious side effects, the animal was terminally anesthetized and underwent necropsy and histopathology.
Safety phase. Dogs were randomly assigned to receive the lumbar intrathecal infusion of the maximum available concentration of ketorolac (5 mg/ml of INTRATHECAL KETOROLAC IN DOGS ketorolac), 0.5 mg/ml ketorolac, or an equal volume of saline delivered at 50 ml/h for a minimum of 28 days, unless euthanasia was deemed necessary.
Pharmacokinetics phase. Serum and lumbar intrathecal CSF samples (0.5 and 0.3 ml, respectively) were taken before and at intervals after the intrathecal injection of ketorolac (5 mg/ml) as a 1 ml bolus and assayed for ketorolac. After a 3-5 day interval, intrathecal infusion of ketorolac (5 mg/ml) at a rate of 50 ml/h was initiated. Before and at 6-12 h after the initiation of infusion, serum, and lumbar CSF samples were taken and assayed for ketorolac. In addition, CSF samples were split and assayed for PGE2.
Dog Clinical Observations
A physical examination of each dog was conducted prior to its inclusion into the study. Animals were observed for health status and clinical signs at least twice daily. Catheters and pumps were checked at least once daily.
Neurological examination. For safety phase animals, a neurological examination was undertaken prior to the initiation of drug delivery and within three days prior to sacrifice (e.g., on or about study Day 25-28). Examinations were performed without knowledge of treatment group.
Periodic observation. After surgery, each dog's rectal temperature was recorded daily. Specific behavioral indices chosen to assess each animal's state of arousal, muscle tone, and motor coordination were undertaken twice daily throughout the in-life phase of the study, as described in detail elsewhere (Yaksh et al., 1997) . Body weights, heart rate, and blood pressure measurements were recorded on Days À5, À3, prior to initiation of test or control article, at regular 4-day intervals, and on the day of necropsy.
Measurement of cardiovascular parameters. Measurements were made using a tail cuff manometer (Dinamap 8100, Criticon). Respiration rates were measured by observation of chest expansion and contraction.
Nociception response. The thermally evoked skin twitch response was measured using a probe with approximately 1 cm surface area maintained at approximately 62.5 6 0.5 C with a feedback controller. The probe was applied to two shaved areas of the back (right and left lateral) at the thoracolumbar level of the spine. Typically, this results in a brisk contraction of the local musculature within 1-3 s of probe placement. Upon the appearance of this response, the probe was removed and the latency to response recorded. Failure to respond within 6 s was cause to remove the probe and assign that value (6 s) as the latency. For analysis purposes, the nociceptive response was presented as the mean of the two latencies.
Dog Laboratory Measurements
Blood analyses. Blood was collected from each dog by cephalic venipuncture, after an overnight fast of approximately 16 h (no food was allowed but free access to water was provided) for a complete blood count and blood chemistry panel.
Complete blood counts included the following analyses: leukocyte, erythrocyte, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, differential leukocyte count (absolute and relative), reticulocyte count, and blood cell morphology evaluation.
Blood chemistry panels included the following analyses: sodium, cholesterol, potassium, aspartate aminotransferase, chloride, alanine aminotransferase, total protein, alkaline phosphatase, albumin, triglycerides, calcium, globulin (calculated), phosphorous, albumin/globulin ratio, creatinine, total and direct bilirubin, glucose, and urea nitrogen. After initiation of test or control article, weekly hematocrit values were determined on site over the duration of the safety phase of the study.
Drug samples. To determine drug concentration in the blood, duplicate cephalic blood samples (41 ml) were collected on wet ice and prepared as serum, then transferred to Eppendorf tubes and stored at À20 6 10 C until analysis. To determine test article concentration in the cerebrospinal fluid (CSF), samples of CSF (approximately 0.3 ml) were collected on ice then transferred to Eppendorf tubes and stored at À20 6 10 C until analysis.
Ketorolac analysis. Serum and CSF samples were quantitatively extracted by C-18 reverse phase cartridge chromatography and eluted with acetonitrile. Concentrated eluates were injected onto an HPLC equipped with a Phenomenex ''Prodigy'' C-18 reverse phase column (250 mm 3 4.6 mm). Peaks were detected withanAgilent Model1100UV detectorset ata wavelengthof313.Allunknowns, standards, and controls contained an equal quantity of internal standard, 200 ng of indoprofen. With this assay, a single peak for ketorolac is found at the retention time of10.68min,the internalstandardindoprofenelutesat12.09min.Plasma and CSF extracts showed no interfering chromatography throughout the integration time period. The absolute sensitivity of the ketorolac assay was 5 ng/ml, and the coefficient of variation was 510% within the concentration range 5-500 ng/ml.
Dog Necropsy
Allanimalswere anesthetizedwith anivdoseofsodiumpentobarbital(35 mg/kg or dose to effect). Blood and cisternal CSF (by percutaneous puncture with a 22 ga spinal needle) were then sampled. The aorta was then catheterized though a thoracotomy and the blood cleared by perfusion with approximately four liters of 0.9% (w/v)salinefollowedbyapproximatelyfourlitersof10%neutralbufferedformalin.
Spinal dissection. After perfusion, the dura of the spinal cord was exposed by laminectomy. Methylene blue dye was injected through the intrathecal catheter to determine the catheter patency, the location of the tip, and dye spread around the tip. The condition of the spinal cord was noted and a photographic (digital) record of the spinal cord/catheter relationship was made. The cord was cut (taking care to keep the dura intact) into four sections: cervical (section A), thoracic (section B), high lumbar (catheter tip region, section C), and lower lumbar (just caudal to catheter tip section D), for histopathological analysis. In addition to the spinal cord, portions of gastrointestinal tract, kidney, and bladder were also retained Tissue preparation. Formalin-fixed tissues were trimmed into cassettes, processed and embedded in paraffin, sectioned at approximately 3-5 mm and stained with hematoxylin and eosin. In addition, special stains were performed on the spinal cord in the block at the catheter tip region (block C). These sections were immunohistochemically stained for glial fibrillary acidic protein (GFAP) (DAKO, Carpenteria, CA; Kit 20334, Lot # CH096302), Gram stain (McDonald's Gram Stain, American Master, Lodi, CA; Kit # KTMGS) for bacteria and Grolcott's Methenamine Silver (GMS), (Grolcott's Methenamine Silver Stain Kit # KTMGSMIC, American Master, Lodi, CA) for fungi. Spinal cord sections were evaluated by light microscopy independently by two pathologists (C.M. and M.G.) without knowledge as to treatment. A text description was written for each section. The severity of the inflammation was graded on a scale of 0-3 for increasing severity, and the animals were then forced ranked in order of increasing severity. To more precisely rank the pathology scores, all slides were re-reviewed, still without knowledge of treatment groups, and within each score category an additional increment of 60.25 could be given if the reaction was slightly more or less severe than that of animals with whole number scores.
Rat Procedures
There were two phases to the rodent studies: intrathecal toxicity and spinal cord blood flow.
Intrathecal toxicity. To assess the response of the intrathecal space to repeated bolus delivery, rats were randomized to receive 50 mg ketorolac or an equal volume (10 ml) 0.9% saline daily by intrathecal bolus for four days (n 5 10 per group). Arousal, motor coordination, paw withdrawal latency to radiant heat, and general behavior were assessed daily after each injection, as previously described (Yaksh et al., 1995) . On day 6, animals were deeply 324 anesthetized with pentobarbital, perfused transcardially with saline followed by paraformaldehyde, the spinal cords removed, fixed, then sectioned and stained with hematoxylin-eosin. Sections of spinal cord near the catheter tip in the lumbar region, and distant from the tip in the thoracic region and cervical region were examined by a pathologist unaware of treatment group.
Spinal cord blood flow. Rats were anesthetized with sevoflurane. Femoral venous and arterial catheters were inserted; then a tracheotomy was performed for controlled ventilation. A small laminectomy was performed at the atlantooccipital membrane, the dura excised, and a tissue well created. A PE 50 catheter was tunneled under the skin of the back, exiting above the spinal cord surface, and the well perfused with saline solution through this catheter. Laser-doppler flow was performed by placement of a flowmeter probe directly over the spinal cord surface. Following baseline measurements, the spinal cord was continuously perfused with saline, followed by ketorolac, 2.5 and then 5 mg/ml. Blood pressure and heart rate were monitored throughout the experiment.
Statistical Analysis
Data of the respective observations (e.g., mmHg, beat/min, mg/ml) are expressed as means and SEs, or as medians and quartiles. Continuous normal data were compared using repeated measures and one-way ANOVA with post hoc Bonferroni tests for multigroup comparisons. Distribution-free testing of data, such as ranked spinal cord pathology, was performed using the Jonckheere test for comparison of three or more groups with post hoc Mann-Whitney U tests for multigroup comparisons. All statistical comparisons were made at the p 5 0.05 level of significance. Pharmacokinetic data were analyzed using PK Solutions 2.0 ( # 1999, Summitt Research Services, Ashland, OH) statistical software for noncompartmental pharmacokinetic data analysis. Analysis included half-lives, descriptive curve parameters, curve area, statistical moment, and volume of distribution calculations.
RESULTS

Dog Investigations
All animals survived the surgical preparation without evidence of significant neurological deficit due to the implantation of the catheters.
Dose-Ranging Phase
There were no significant changes in motor function, cardiovascular status, or body temperature in either dog receiving 5 mg/ ml, 100 ml/h. However, due to prominent tarry stools, a significant lowering of hemtocrit (pre vs. post: 47% to 27% and 41% to 25%) and deteriorating physical condition, ketorolac infusion (5 mg/ml, 100 ml/h) of dog 3376087 was terminated on day 13, and this animal was euthanized on day 18. Dog 3381293 displayed blood in stools and some deterioration of physical status, but was infused until euthanasia on infusion day 34. It was considered that these outcomes reflected the systemic effects arising from the daily dose of ketorolac of 2 mg and 1.3 mg/kg/day, respectively, based on body weight at the time of termination of infusion. Serum ketorolac concentrations at sacrifice were 7.83 and 3.36 mg/ml, respectively. Inspection of the spinal cord revealed no pathology (see Table 4 ). Based upon these results, the ketorolac concentration of 5 mg/ml was retained, but the infusion rate for the safety phase was reduced to 50 ml/h.
Safety Phase
All vehicle dogs, six of eight 0.5 mg/ml test article dogs and five of the six 5 mg/ml test article dogs completed the 28-day infusion sequence. The two 0.5 mg/ml dogs (3892328 male, 3884376 male) were euthanized at day 13 and 23, respectively, and the single 5 mg/ml test article dog (CPH AER, female) was sacrificed at day 10 of infusion.
Behavioral and Physiological Observations
Neurological examination. Baseline behavioral scores for arousal, muscle, and motor coordination were scored as '0' or '1' at the start of infusion. In vehicle animals, all neurological signs were judged minor and limited to mild increases in hind limb motor tone and minimal gait abnormalities. Behavioral manifestations, i.e., arousal, muscle tone, and motor coordination, were typically scored as '0' or '1' throughout the interval of infusion. In the 0.5 mg/ml treatment group, six of the eight displayed minimal neurologic changes comparable to the vehicle group, with behavioral scores typically '0' or '1'. However, two animals, 389 2328 and 388 4376, were euthanized at day 13 and 23, respectively, due to progressive hypertonicity of the neck and hind limbs, and pain behavior. These conditions developed between days 9 and 13 for dog 389 2328 and days 14 to 20 in dog 388 4376. In the 5 mg/ml treatment group, as in the vehicletreated group, all abnormalities identified were minimal and typically reflected mild hind limb and minimal gait impairment, with behavioral scores for arousal, muscle tone, and motor coordination typically scored as '0' or '1' throughout the interval of infusion. A single 5 mg/kg dog (CPH AER, female) was sacrificed at day 10 of infusion due to the acute development of a lateral recumbent posture and whole body stiffness.
Physiological measures. Pre-infusion values for temperature (101.8 6 0.6 C), respiration (30 6 4 b/m), heart rate (125 6 21 b/m), and blood pressure (diastolic: 79 6 16; mean: 99 6 17; systolic: 136 6 17 mmHg) were comparable for each group. Over the interval of the infusion, no treatment group displayed any clinically significant trend in these indices in any animal, even in those undergoing early sacrifice.
Body weight. Mean body weight upon initiation of infusion was 9.7 6 0.5 kg and did not differ between treatment groups. Neither the test nor control article treatments had a significant effect upon mean body weight. CPH AER displaying significant falls in hematocrit and euthanized at 10 days showed a 13% decrease in body weight over the interval of test article administration (see below).
Nociceptive response. Baseline thermal escape latencies were 3.6 6 0.4 s. There were no significant changes in this thermal escape latency over time in any treatment group.
Clinical Chemistry
Blood chemistry values were not different among the three groups at surgery, and the medians for selected INTRATHECAL KETOROLAC IN DOGS 325 values are presented in Table 2 . Examination and statistical comparison of these parameters at the time of sacrifice reveals no systematic dose-dependent effects. As noted, several animals underwent early sacrifice or showed distinct reactions, and theirdata are presented separately to permit independent assessment. Hematocrit/RBC. As indicated in Table 2 , there were no systematic changes between surgery and sacrifice in animals receiving vehicle. Dogs receiving 0.5 mg/ml ketorolac typically displayed a slight ( < 15-20%) reduction in hematocrit and red blood cell count. With the 5 mg/ml infusion (50 ml) treatment, one of six dogs displayed a prominent drop in hematocrit and RBC count. Red cell count paralleled the changes noted in the respective hematocrit. As noted above, both animals receiving the higher infusion dose showed prominent drops in hemtocrit values.
WBC/neutrophils. Animals in vehicle and ketorolac treatments typically displayed little or no change in WBC and neutrophil counts (Table 2) . Treatment animals undergoing early sacrifice or showing prominent dysfunction typically showed an increase in both WBC and neutrophil count.
CSF analysis. Summaries of cisternal CSF clinical analysis results are presented in Table 2 . Mean CSF protein and glucose were not different among treatment groups at the time of surgery.
Vehicle and both test article groups displayed increases in protein at sacrifice. Cisternal glucose levels were within expected ranges before and at the time of necropsy, except for animal 385 8979 in the 0.5 mg/ml ketorolac group. White blood cell counts showed an increase over the 28-day period that was similar in both vehicle and test article groups. Differential cell counts showed a similar profile for both vehicle and test article groups. Statistical comparison of these parameters at the time of sacrifice reveals no dosedependent differences among treatment groups ( p 4 0.10). In the animals undergoing early sacrifice, cisternal CSF protein concentrations were notably elevated (see Table 2 ). CSF glucose levels were comparable at sacrifice in all animals with the exception of low glucose levels in 3858979, 388437, and 3376087, the latter two of which underwent early sacrifice.
Necropsy Observations
Catheter. Examination of the external catheter tracts typically revealed a well-healed sheath encasing the catheter as it exited from the cisternal membrane. The presence of serous fluid was noted along the sc catheter track in two 0.5 mg/kg dogs (3884376; 3858979) and one 5.0 mg/kg dog (CPH AER) (see Table 2 ). Intrathecal injection of 0.2 ml of methylene blue dye uniformly revealed coloration at the tip indicating patency and continuity.
Spinal cord. No visually evident abnormalities were typically present in the spinal canal at the catheter sites at necropsy. However, in two 0.5 mg/kg dogs (3892328; 3858979) and one 5.0 mg/kg dog (CPH-AER), unclotted blood was noted in the cisterna and upper cervical spinal cord.
Other tissues examined. Administration of 5 mg/ml ketorolac (50 ml/h) was associated with gastrointestinal ulceration in two of six animals (CPH AYU and CPH AZX) and, as noted above, in both animals receiving 5 mg/ml at 100 ml/h. Small intestinal mucosal infiltration with lymphoid and monocytic cells, and edema was present in dog CPH AER. Mild pulmonary congestion and thrombosis were noted in Dog CPH AER. Tissue from other organs was not examined by the histopathologist, however, no other gross abnormalities were noted at necropsy. With the low (0.5 mg/ ml) infusion concentration no evidence of gastric bleeding or other untoward systemic effects were noted.
Spinal Histopathology
Table 3 presents the summary of the incidence of pathology observations and scores for the four treatment groups. Table 4 presents the individual pathology score presented by animal and spinal level. In general, observations may be considered in terms of local catheter compression of the spinal cord, the presence of dural and arachnoid infiltrates, and root and spinal infiltrates at the three levels of the spinal cord that were systematically examined. Several points summarize the overall assessment.
Spinal cord compression. A modest spinal cord compression adjacent to the catheter was noted with an equal incidence in all four treatment groups, along the axis of the catheter but not below the catheter tip (Table 3 ; see Fig. 1 ).
Local inflammatory reaction. The incidence of inflammatory infiltrates in dura, nerve root, and spinal cord was noted with approximately equal incidence observed at all levels in all four treatment groups (Table 3) . At the catheter tip site (section C), where drug concentrations are highest, the local reaction was judged to be minimal to mild (score of 1.25 or less) in four of six control animals, five of eight 0.5 mg/ml treated animals, and five of six animals in the 5 mg/ml treated group. In these animals, a small fibrous track inside the dural sac represented the catheter track (see Figure 1A ). Minimal to mild chronic inflammation was associated with the tracks, consisting of small numbers of lymphocytes, plasma cell, and macrophages around the catheter site and in the adjacent dura. In the remaining two animals in the control group (CPHATW, CPH AVH), three animals in the 0.5 mg/ml treated group (3892328, 3884376, 3858979) and one animal in the 5 mg/ml (CPH AER) treated group, moderate to severe inflammation (score of 1.5 or greater) was present in block C (catheter tip). One dog had white matter vacuolization Spinal level Cervical Saline 50 ml/h 2/6 5/6 3/6 1/6 0/6 0.75 0.5 mg/ml 50 ml/h 2/7 4/7 6/7 2/7 2/7 1.0 5 mg/ml-50 ml/h 3/6 5/6 6/6 3/6 2/6 1.5 5 mg/ml-100 ml/h 1/2 2/2 1/2 2/2 0/2 (1.5) Thoracic Saline 50 ml/h 1/6 6/6 3/6 1/6 2/6 0.87 0.5 mg/ml 50 ml/h 1/7 7/7 7/7 1/7 2/7 1.0 5 mg/ml-50 ml/h 2/6 6/6 6/6 1/6 2/6 1.5 5 mg/ml-100 ml/h 2/2 2/2 2/2 (1.9) Lumbar (tip) Saline 50 ml/h 1/6 5/6 2/6 1/6 1/6 1.0 0.5 mg/ml 50 ml/h 4/7 7/7 7/7 2/7 1/7 1.0 5 mg/ml-50 ml/h 1/6 6/6 6/6 3/6 2/6 1.0 5 mg/ml-100 ml/h 0/2 2/2 1/2 1/2 1/2 1.5 (?) Lumbar (distal) Saline 50 ml/h 0/6 5/6 5/6 4/6 2/6 1.0 0.5 mg/ml 50 ml/h 0/7 1/7 7/7 0/7 1/7 0.75 5 mg/ml-50 ml/h 0/6 5/6 5/6 2/6 2/6 1.0 5 mg/ml-100 ml/h 0/2 2/2 2/2 1/2 0/2 1.0(?)
Note. Chi square analysis across treatments (vehicle, 0.5 mg/ml, and 5.0 mg/ml) for each class of histological observation vs. treatment at each spinal level revealed no statistical significance at a critical value corresponding to p 5 0.10. Abbreviations: fb: fibroblasts; lym: lymphocytes; pmn: polymorhonuclear leucocytes. Note. Inflammationseveritykey:0 5 noabnormalfindings;1 5 mild;2 5 moderate;3 5 severe;incrementsof60.25inscoreindicatedslightlylessormoresevere than whole number score. Control 5 saline at a volume of 1.2 ml/day, 0.5 and 5 mg/ml ketorolac intrathecally at a volume of 1.2 ml/day. Rank order comparison across treatmentgroupsateachspinallevelwascarriedoutusingtheJonckheererankedtestfororderedmeansateachspinallevel.Comparisonofgrouppathologyscoresacross treatment at lumbar distal, lumbar tip and cervical were not statistically significant (p 50.10), while comparison across dose at the thoracic level was (p 5 0.05).
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(without inflammation); this was focal and not associated with the catheter site. Consistent with this summary, the median pathology scores for sections C and D were not different across treatment group (Jonckheere test p 4 0.10). Consideration of the individual animals presented in Table 3 emphasizes that the most severe histopathology reactions were observed in animals with low CSF glucose at sacrifice (3884376; 3858979, 3376087) .
At sites cephalad to the catheter tip (section A: cervical and B: thoracic) a continuation of the reaction observed distally was typically noted (see Figs. 1B and 1D ). The sections with inflammation showed variable proportions of lymphocytes, neutrophils, plasma cells, and macrophages. In some animals, the inflammation involved spinal nerve roots and epi/perineurium. A variable degree of fibrosis was noted at the catheter site and in adjacent dura, sometimes with neovascularization. Two animals (389 2328 and CPH ATW) had focal lymphocytic infiltration of the white matter adjacent to the catheter site and one (CPH AVL) had a focal lymphocytic infiltrate along the Virchow-Robin spaces. Two animals (385 8979, 0.5 mg/ml ketorolac and CPH AER, 5 mg/ml ketorolac) had extensive infiltration of the spinal cord parenchyma by predominantly neutrophils, with focal necrosis and abscess formation. Statistical comparison across groups revealed a statistical significance by dose for section B (thoracic: p50.05) but not section A (cervical: p40.10).
In all treated and control groups, spinal GFAP staining was within normal limits, even at sites adjacent to the catheter site indicating alack of reactive gliosis.
Gram and GMS stains undertaken in block C (catheter tip) revealed no signs of bacteria or of fungal elements.
Toxicokinetics of Safety Animals
Infusate. Analysis of injectate (ketorolac 5 mg/ml) indicated that representative aliquots contained 5375 6 58 mg/ml of ketorolac (N 5 5).
Serum.
No animal showed ketorolac levels in their serum prior to initiation of infusion. The vehicle treatment group did not show detectable drug levels in serum after 28 days of infusion. In animals receiving ketorolac infusion, the mean serum ketorolac concentrations on day 4, the first time point after infusion initiation, were 0.18 6 0.05 mg/ml and 1.14 6 0.25 mg/ml for 0.5 mg/ml and 5 mg/ml ketorolac infusions, respectively. Serum concentrations measured at the time of sacrifice did not differ for these respective treatments. In the one animal (CPH AER, 6.0 kg) in the 5 mg/ml test article treatment group that was euthanized on day 10 of infusion because of gastric ulceration, maximum serum ketorolac levels were 2.08 mg/ml. As expected, small animals (such as CPH AER) displayed the highest serum ketorolac concentrations.
Cisternal CSF. No animals showed any drug levels in pretreatment cisternal CSF. The vehicle group did not show drug in cisternal CSF after 28 days of infusion. After 28 days of continuous infusion, the test article treatment groups had mean cisternal CSF drug levels of 0.06 6 0.03 mg/ml and 0.16 6 0.09 mg/ml (0.5 mg/ml and 5 mg/ml groups, respectively) in the cisternal CSF. The mean cisternal CSF to serum ratio measured at the time of necropsy was 0.32 6 0.15 and 0.10 6 0.07 for the 0.5 mg/ml and 5 mg/ml treatments, respectively.
Intrathecal Pharmacokinetics
All pK animals survived the experiments without disability. One animal CRD ATI failed to sample after the initial studies and was removed from further analysis. At necropsy, the intrathecal infusion catheters were typically located at L1/2 and the sampling catheter was approximately 2 cm proximal to that of the infusion catheter. Examination of the spinal cords revealed no evidence of gross pathology or any sign of blood in the intrathecal space.
Bolus intrathecal injections and ketorolac concentrations.
The bolus intrathecal delivery of ketorolac (5 mg/ml/1 ml) in three dogs resulted in an initial peak concentrations in lumbar   FIG. 2 . Ketorolac (mg/ml) in lumbar CSF and serum of three dogs after bolus lumbar intrathecal injection (T 5 0) of ketorolac (5 mg/1 ml). (Kinetic data for these experiments are presented in Table 5.) INTRATHECAL KETOROLAC IN DOGS CSF and plasma, and this declined in a biphasic fashion (Fig. 2) . Calculations of lumbar CSF kinetic parameters, assuming a onecompartment model, are presented in Table 5 . At the time of peak serum concentration, the CSF/serum ratios were approximately 30:1.
Continuous infusion and ketorolac concentrations.
To determine steady state levels of ketorolac in CSF, lumbar CSF samples were harvested before and at 24-48 h after initiation of ketorolac infusion in three animals. As indicated in Figure 3 , ketorolac concentrations at 0.5 and 5.0 mg/ml at 100 ml/h were on the order of 3.8 and 53 mg/ml, respectively.
Effects on Lumbar CSF PGE2 Levels
Mean lumbar CSF PGE2 concentrations measured in six dogs prior to the delivery of ketorolac were 1224 6 26 pg/ml. After the bolus delivery of ketorolac (5 mg/ml; 1 ml), there was a significant reduction (48%) in the concentrations of lumbar PGE2 at 30 min with significant recovery being observed by 4 h (see Fig. 4 ). After the initiation of intrathecal ketorolac infusion (0.5 mg/ml) in three dogs, lumbar PGE2 concentrations were significantly depressed from baseline 1271 6 18 to 87 6 22 at 24 h.
Rat Investigations Safety Phase
All animals completed the series of injections, and there were no alterations in behavior. Ketorolac-injected animals did not differ from saline-injected animals in assessment of motor tone, coordination, and arousal (data not shown). Similarly, weight did not differ before intrathecal drug treatment (288 6 19 g in saline; 304 6 21 g in ketorolac) at the end of drug treatment (289 6 22 g in saline; 305 6 18 g in ketorolac), or on any day during treatment (data not shown). Latency to paw withdrawal did not differ prior to or following intrathecal drug delivery and baseline withdrawal latencies did not change over the time course of drug treatment (data not shown).
Necropsy. At post mortem, spinal cords, meninges, and nerve roots appeared grossly normal in all animals. Perfusion was inadequate in one animal (in the saline group).
Histopathology. Histological examination showed a rim of fibrin, fibroblasts, and inflammatory cells around the catheter site. Histological changes were observed frequently in both groups, but with no difference in incidence between groups. At the lumbar level, the number of animals with no significant Note. D, distribution; E, elimination; C, concentration; MRT, mean residence time; AUC area under the curve; obs, observed; Vd, volume of distribution.
a Regression analysis run on grouped data.
FIG. 3.
Left: Lumbar CSF Ketorolac concentrations (mean and individual data) at T 5 À15 min (Pre) and 24-48 h after the initiation of intrathecal infusion of ketorolac (0.5 and 5 mg/ml/100 ml/h) in three dogs. Right: Ratio of lumbar CSF ketorolac measured versus that measured during infusion with 0.5 mg/ml at 100 ml/h. 330 lesions, and minimal multifocal white matter vacuolation was three, five, and one in saline-treated animals and one, seven, and two in ketorolac-treated animals. The white matter vacuolation was swelling of myelin sheaths, some of which contained myelin fragments and cellular debris. These changes, when present, were in all funiculi and at all dermatomal levels, not consistent with a focal lesion of the cord.
Spinal cord blood flow. Laser-Doppler flow remained stable following establishment of the experimental model, and was not altered over 30 min of saline perfusion. Ketorolac, either at the 2.5 or 5.0 mg/ml concentration, had no effect on SCBF, as measured by relative change in blood flow velocity (Fig. 5) .
DISCUSSION
Spinal Cyclo-oxgenase
Cyclo-oxygenase (COX) inhibitors suppress hyperalgesia that arises secondary to tissue injury. In contrast to the broadly held belief that NSAID have a peripheral action, these agents exert a potent antihyperalgesic action following spinal delivery (Malmberg and Yaksh, 1992a,b; Yaksh, 1982; . This spinal effect reflects three observations: 1) cyclooxygenases are constitutively expressedin spinal parenchyma; 2) afferent input evokes spinal prostaglandins release; 3) prostanoids exert a facilitatory effect on spinal nociceptive neurons (Svensson and Yaksh, 2002; . While it is clear that systemically delivered NSAIDs can exert central effects, the relative central bioavailability of agents such as ketorolac is poor (Rice et al., 1993) . Given the peripheral side effect (e.g., antiplatelet action), the central effects of a systemic agent may be limited by the peripheral dose effects. This raises the possibility of considering spinal delivery. Cancer patients received pain relief from intrathecal lysine acetylsaliscylate, suggesting a spinal action in humans (Devoghel, 1983 (Devoghel, , 1993 Pellerin et al., 1987) . Nevertheless, prior to human intrathecal delivery, preclinical evaluation of ketorolac safety by this route must be ascertained. Ketorolac (Acular PF) is a sterile preservative-free formulation provided in concentrations of 5 mg/ml. We examined continuous 28-day intrathecal infusion of the highest available concentration of drug at a dose that could be tolerated by the dog and 1/10 this highest tolerated concentration. In the rat, the standard bolus injection volume is 10 ml and, accordingly, the highest concentration was delivered in that volume, and the effects of the injections on spinal blood flow were examined.
Intrathecal Safety Assessment
Spinal drug safety has two components: untoward physiological effects mediated by spinal and nonspinal systems, and local tissue toxicity. In the first case, the effects are proportional to the total delivered dose. Such outcomes reflect a direct effect on spinal or extra-spinal mechanisms and often define the maximum dose of drug to which the dog can be exposed. The limiting response for opiates is defined by respiratory depression (Sabbe et al., 1994) ; for clonidine it is hypotension and sedation. Conversely, tissue toxicity is dependent upon the concentration to which the local tissue proximal to the delivery site is exposed. Accordingly, the most robust test of safety will be consideration of the tissue reaction to the highest concentration that can be delivered. In this case, the available GMP, preservative-free formulation of ketorolac is 5 mg/ml.
Dose/Concentration Selection
In the dose-ranging series, we observed that 5 mg/ml, 100 ml/h (total dose of 12 mg/day, approximately 1-1.5 mg/kg) resulted in a reduced hematocrit and gastrointestinal bleeding. Accordingly, the infusion rate in was lowered to 50 ml/h to reduce the total systemic dose by half. This permitted us to retain the highest local spinal exposure and reduce, but not abolish, systemic toxicity.
Intrathecal Ketorolac Effects
Under the present treatment paradigm, all animals including the saline-control dogs displayed a mild local meningeal inflammatory reaction and elevated cisternal CSF protein at the time of sacrifice. Inflammation at the catheter tip site was noted with approximately equal incidence in control, 0.5 mg/ml, and 5 mg/ml treated group. At the site of highest drug concentration (the catheter tip), there were only modest effects in all groups and none were statistically drug/dose related. Interestingly, group scores revealed an elevation of pathology score only for thoracic sections. No difference was noted in cervical sections. This lack of difference in pathology scores for lumbar sections proximal to the catheter tip where drug level is highest makes it difficult to interpret the significance of the thoracic response. Finally, although the higher dose of ketorolac (5.0 mg/ml/100 ml/h) was not systematically examined, the incidence and magnitude INTRATHECAL KETOROLAC IN DOGS of the spinal pathology was not different from that observed at the lower doses. These incidental observations over a 10-fold range of concentration and a 20-fold range of dosing confirm the lack of an effect of ketorolac at these concentrations on spinal tissue. These results are in accord with those of Gallivan et al. (2000) who studied repeated epidural bolus delivery of ketorolac in dogs and observed no untoward effects on spinal structure.
While there were no group differences, three animals had severe acute inflammation in the spinal cord parenchyma, two (3858979 at all spinal levels and 3884376 at thoracic level) in the 0.5 mg/ml group and one (CPH AER at all levels) in the 5 mg/ml group. These observations reflect several variables. First, these animals displayed systemic neutropenia and reduced cisternal CSF glucose (when determined), a profile suggestive of a bacterial infection. The severity of the effect upon CSF could not be determined at necropsy from the third animal with severe spinal cord inflammation. This animal was the smallest animal and had the most severe gastrointestinal and adverse systemic responses. Gram stains undertaken at the catheter tip were negative in all animals. This, however, does not exclude that a peri-catheter infection at other loci contributed to this picture. This suggestion is supported by the observation of serous fluid along the external subcutaneous catheter tract at necropsy in these animals.
Neuraxial bleeding. Blood was noted in the cisterna and upper cervical cord at sacrifice in two 0.5 mg/kg and one 5.0 mg/kg dog. No bleeding was observed in other animals or vehicle-treated dogs. As there was a percutaneous cisternal tap approximately 30 min prior to death, it is possible that the observation of local cisternal blood reflects an event secondary to a traumatic puncture. The presence of persistent blood ketorolac might facilitate such bleeding. The fact that bleeding was not observed in any animal intraparenchymally, or at the lumbar level where drug concentration was highest supports a local event at the cisterna. The importance of persistent anticoagulation in this outcome is suggested by the absence of cisternal bleeding in vehicle animals and in pharmacokinetic dogs receiving intrathecal ketorolac by bolus and by infusion for two-day intervals.
Rat Studies
The absence of specific intrathecal drug related toxicity in the dog was mirrored by the studies carried out in the rat. Here moderate catheter-related pathological changes were noted. These effects were not altered by ketorolac. Further, consistent with previous work suggesting that prostaglandins have minimal effects on central perfusion (Siesjo and Nilsson, 1982) , local ketorolac had no effect upon spinal blood flow.
Model Reliability
Spinal agents may lead to local reactions including aseptic inflammation, neuronal death, and demyelination (Weller, 1999) , which are driven by local drug concentration and duration of exposure. (Yaksh et al., 1999b) The most robust assessment of toxicity is provided by continuous delivery of the drug into the local intrathecal space at the highest available concentration. (Yaksh et al., 1999b ) Accordingly, we employed the highest concentration and dose consistent with survival and applied this by continuous infusions for an interval of 28 days. Given an absence of tissue effect, an important question is how sensitive is the test model in displaying toxicity. To date, a variety of agents have examined in this dog model, including baclofen (Sabbe et al., 1993) ; clonidine ; adenosine (Chiari et al., 1999) ; neostigmine (Yaksh et al., 1995) ; and brainderived nerve growth factor (Yaksh et al., 1997) . Morphine given for 28 days as a bolus was also without effect (Sabbe et al., 1994) . In contrast, the opioid peptide DPDPE and high concentrations of morphine are associated with toxicity after 28-day continuous infusion. The canine model is thus both robust and sensitive.
Intrathecal Ketorolac Kinetics
Intrathecal ketorolac showed a biphasic clearance after bolus delivery. This clearance is consistent with a small moderately lipid soluble molecule that is cleared from the CSF compartment first by an initial distribution followed by clearance. Inulin, a small molecule shows a similar biphasic clearance with similar T1/2 values (Yaksh et al., 1997) . Importantly, continuous infusion of 0.5 and 5 mg/ml gave rise to lumbar CSF concentration of approximately 4 and 53 mg/ml respectively, suggesting that the CSF kinetics of intrathecally infused ketorolac are linear.
Intrathecal Ketorolac Efficacy
In the dog, the available pain models involve thermal escape (e.g., skin twitch). COX inhibitors have little effect upon such acute nociceptive processing (Svensson and Yaksh, 2002) . Accordingly, based on rodent data (Svensson and Yaksh, 2002) , we anticipated that IT ketorolac would have no effect upon this end point. However, measurement of prostaglandins levels in the lumbar cerebrospinal fluid revealed depression of the basal levels after bolus and infusion. Suppression was greatest with continuous infusion. Delivery of 1.2 mg over 24 h (e.g., 0.5 mg/ml) resulted in a greater reduction in CSF PGE2 levels than when 5 mg was delivered as a bolus. As suppression of prostanoid synthesis reflects the essential mechanism of ketorolac, we conclude that achieving CSF concentrations of 4 mg/ml of ketorolac in the CSF leads to a prominent biological action.
Intrathecal Ketorolac Therapeutic Ratio
In the rat, it has been shown that intrathecal; ketorolac (10 mg/ 10 ml) bolus can produce a potent analgesia Yaksh, 1992a.b., 1993) . In the present study, we undertook 332 YAKSH ET AL. repeated bolus delivery of 50 mg/10 ml) of ketorolac. This is the maximum dose that can be delivered given the standard injection volume of 10 ml and available ketorolac concentration. At this maximum concentration/dose, no untoward spinal toxicology was noted. Accordingly, we suggest that the therapeutic index (toxic dose/effective dose) for analgesia in the rodent exceeds five. In so far as concerns the dog, the suppression of PGE2 concentration is a surrogate marker. We assert that a maximal suppression of CSF-PGE2 concentration as compared to control was observed with continuous infusion of 0.5 mg/ml yielding a CSF concentration of 4 mg/ml. As spinal tissue toxicity was not observed at a mean steady CSF concentration of ketorolac of approximately 50 mg/ml (produced by 5 mg/ml), we suggest that the therapeutic ratio as measured by ketorolac concentration in the CSF or infused dose readily exceeds a factor of 10.
Relationship of Preclinical Safety Data to Humans
The 'robustness' of the assertion of intrathecal safety is defined by the degree to which the preclinical exposure exceeds that to which the human will be exposed. Accordingly, to the degree that local concentration defines toxicity, we conclude that 28 days of exposure to a local CSF concentration of approximately 50 mg/ml (as produced by the continuous infusion of 5 mg/ml) has minimal drug related toxicity. As for bolus delivery, we note that after the bolus delivery of 5 mg in 1 ml, the initial CSF concentration was approximately 3000 mg/ml or a factor of 60 (i.e., 3000/60) greater. In previous work, we noted that the local acute dilution volume of the lumbar space of the dog is conservatively 1/3 of the human, i.e., for any given dose the human will dilute the bolus injection by a factor three times greater than the dog (Sabbe et al., 1993) . Therefore, assuming linear kinetics we would argue that the initial bolus dose of ketorolac in humans would be 5 mg/ml 3 1/60 3 3 5 250 mg/ml. These are admittedly crude calculations, but provide a conservative first approximation of the dose and concentration for bolus delivery that should give a local concentration in the human that was tolerated for 28 days in the preclinical model. Based on these studies, a Phase 1 bolus dose ranging trial was undertaken with intrathecal ketorolac in humans with no significant events (Eisenach et al., 2002) .
With regard to continuous infusion, it is clear that in the dog, the limiting side effects at the 5 mg/ml concentration was total dose, At doses greater than 6 mg/day (corresponding to approximately 0.6 mg/kg over 24 h in a 10 kg dog or chronic serum concentrations of 1.1 mg/ml) systemic gastrointestinal effects and reductions in hematocrit were evident. In humans, a single bolus analgesic dose of ketorolac (approximately 0.4 mg/kg yields peak plasma levels of 2-3 mg/ml; Brocks and Jamali, 1992) can indeed yield significant and long lasting (24 h) changes in coagulation parameter (Niemi et al., 2000) . Doubtless chronic exposure with these serum concentrations would be poorly tolerated and such considerations must temper any chronic ketorolac application in humans.
